ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of va...

詳細記述

保存先:
書誌詳細
出版年:Front Neurol
主要な著者: Lingor, Paul, Weber, Markus, Camu, William, Friede, Tim, Hilgers, Reinhard, Leha, Andreas, Neuwirth, Christoph, Günther, René, Benatar, Michael, Kuzma-Kozakiewicz, Magdalena, Bidner, Helen, Blankenstein, Christiane, Frontini, Roberto, Ludolph, Albert, Koch, Jan C.
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2019
主題:
Neurology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6446974/
https://ncbi.nlm.nih.gov/pubmed/30972018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.00293
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料